Company and Stock Identity
How Waco Cardiology Associates Connects to the Public Market
- Company structure
- Private cardiology practice
- Market access
- No current public listing was verified.
- Research focus
- Keep the practice and the research operation apart in your head, because only one of them changed hands. Patients still see the same cardiologists in the same building; the trials those patients can join are now run by a national network. The question that follows is whether the investigators stayed. A research site is worth buying for its principal investigator and its enrolled patients, and both can walk. The published participant figure of 200 to 250 is the number to watch, because a site network that counts locations rather than patients can grow on paper while enrolment falls.
The practice about page, read on 2026-11-14, says Waco Cardiology Associates has cared for Central Texans since it was founded in 1971 and calls itself one of the largest cardiovascular practices in the area. That page lists twelve physicians, six advanced practice providers and one further doctor at a heart failure clinic, and names no parent company or health system owner. The practice itself was not sold. What changed is its research arm: the Waco Tribune-Herald report carried on the Iterative Health newsroom, dated 8 June 2026, says the clinical research operation at the practice was bought as part of a three city deal covering Waco, Port Arthur and Beaumont, and that the site had 200 to 250 trial participants enrolled at the time. Checked on 2026-11-14.
Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.
First-Hand Company News
Latest Developments
Iterative Health buys three Texas cardiology research sites from NextStage Clinical Research
Iterative Health said on 14 May 2026 that it had acquired three cardiology research sites from NextStage Clinical Research, located in Beaumont, Port Arthur and Waco, Texas. Jonathan Ng, founder and chief executive of Iterative Health, is quoted calling the established sites a key addition as the company builds out its cardiology focus within its global network. Donald S. Cross, a cardiologist and principal investigator at Waco Cardiology Associates, is quoted calling the move a natural next step for the site staff and the patients they serve. The announcement states no purchase price and no other financial terms. A later Waco Tribune-Herald report carried on the same newsroom, dated 8 June 2026, adds that the Waco research operation had 200 to 250 trial participants enrolled.
Why it matters: This is a company buying the thing it used to sell software to. Iterative Health has been measuring trials with AI; owning the sites means it now controls enrolment, the scarcest resource in clinical research, and can promise a sponsor patients rather than tools. It also moves the company into cardiology, a long way from the gut disease work it is known for. The risk sits in the same place as the value. A research site is mostly its principal investigator and the patients who trust that person, and neither is a transferable asset. The quote from the Waco investigator reads as a signal that the staff are staying, which is exactly what a buyer needs, but it is a statement of intent made on the day of the deal. With no price disclosed, there is also no way to judge what the company paid for 200 to 250 enrolled patients, which is the number that makes a site worth owning.
Careers and Qualifications
What to Know Before Applying
Work areas: The practice runs its own careers page. What the about page shows about the shape of the work is a cardiology group with diagnostic, interventional and cardiac rehabilitation services in one place, plus advanced practice providers alongside the physicians, so the roles span clinic, procedure suite and rehabilitation rather than one setting.
Qualification signal: A practice that has been independent since 1971 and now hosts a national research network is two jobs at once. For clinical roles, the useful experience is a busy community cardiology service rather than an academic centre. For anyone near the research side, the signal is having worked on trial enrolment inside a practice where patient care comes first, because that tension is the real job and it got harder when the research arm changed owners.
Check current roles at Waco Cardiology Associates. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.
Related Healthcare AI Roles
Training to Compare
- AI for Medicine Specialization ... DeepLearning.AI, delivered on Coursera, about 72 hours, 3 courses
Buyer Snapshot
- Best-fit buyer
- Trial sponsors, research site leaders, physician group executives weighing a research partnership, and investors reading a site network roll up
- Primary use case
- Host and staff clinical trials inside a community medical practice, and enrol patients who would otherwise never be offered a study
- Typical deployment
- Physician practice, specialty group, or research site operator. AI arrives through a sponsor or a research network partner rather than through a software purchase.
Evidence questions
- How many of the named sites are actively enrolling patients right now, rather than contracted?
- Who measured the enrolment result, the network or the sponsor paying for it?
- Did patient volume survive the acquisition, or did the investigators leave with it?
Regulatory and workflow questions
- Who holds the regulatory responsibility for the study at each site after an acquisition?
- Which review board oversees the trials, and did it change when ownership changed?
- How is informed consent handled when a practice becomes part of a research network?
Data and contract questions
- Which patient data leave the practice, who receives them, and in what form?
- Can the practice still see the study results it helped produce?
- What happens to the research data if the network is sold again?
Evidence and Regulation
FDA Clearances on Record
No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.